Copyright Reports & Markets. All rights reserved.

Global LATAM Adalimumab Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 LATAM Adalimumab Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global LATAM Adalimumab Market Size Growth Rate by Product
      • 1.4.2 Oral Type
      • 1.4.3 Injection Type
    • 1.5 Market by End User
      • 1.5.1 Global LATAM Adalimumab Market Size Growth Rate by End User
      • 1.5.2 Rheumatoid Arthritis
      • 1.5.3 Psoriasis
      • 1.5.4 Crohn’s Disease
      • 1.5.5 Ulcerative Colitis
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global LATAM Adalimumab Market Size
      • 2.1.1 Global LATAM Adalimumab Revenue 2014-2025
      • 2.1.2 Global LATAM Adalimumab Sales 2014-2025
    • 2.2 LATAM Adalimumab Growth Rate by Regions
      • 2.2.1 Global LATAM Adalimumab Sales by Regions
      • 2.2.2 Global LATAM Adalimumab Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 LATAM Adalimumab Sales by Manufacturers
      • 3.1.1 LATAM Adalimumab Sales by Manufacturers
      • 3.1.2 LATAM Adalimumab Sales Market Share by Manufacturers
      • 3.1.3 Global LATAM Adalimumab Market Concentration Ratio (CR5 and HHI)
    • 3.2 LATAM Adalimumab Revenue by Manufacturers
      • 3.2.1 LATAM Adalimumab Revenue by Manufacturers (2014-2019)
      • 3.2.2 LATAM Adalimumab Revenue Share by Manufacturers (2014-2019)
    • 3.3 LATAM Adalimumab Price by Manufacturers
    • 3.4 LATAM Adalimumab Manufacturing Base Distribution, Product Types
      • 3.4.1 LATAM Adalimumab Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers LATAM Adalimumab Product Type
      • 3.4.3 Date of International Manufacturers Enter into LATAM Adalimumab Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global LATAM Adalimumab Sales by Product
    • 4.2 Global LATAM Adalimumab Revenue by Product
    • 4.3 LATAM Adalimumab Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global LATAM Adalimumab Breakdown Data by End User

    6 North America

    • 6.1 North America LATAM Adalimumab by Countries
      • 6.1.1 North America LATAM Adalimumab Sales by Countries
      • 6.1.2 North America LATAM Adalimumab Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America LATAM Adalimumab by Product
    • 6.3 North America LATAM Adalimumab by End User

    7 Europe

    • 7.1 Europe LATAM Adalimumab by Countries
      • 7.1.1 Europe LATAM Adalimumab Sales by Countries
      • 7.1.2 Europe LATAM Adalimumab Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe LATAM Adalimumab by Product
    • 7.3 Europe LATAM Adalimumab by End User

    8 Asia Pacific

    • 8.1 Asia Pacific LATAM Adalimumab by Countries
      • 8.1.1 Asia Pacific LATAM Adalimumab Sales by Countries
      • 8.1.2 Asia Pacific LATAM Adalimumab Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific LATAM Adalimumab by Product
    • 8.3 Asia Pacific LATAM Adalimumab by End User

    9 Central & South America

    • 9.1 Central & South America LATAM Adalimumab by Countries
      • 9.1.1 Central & South America LATAM Adalimumab Sales by Countries
      • 9.1.2 Central & South America LATAM Adalimumab Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America LATAM Adalimumab by Product
    • 9.3 Central & South America LATAM Adalimumab by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa LATAM Adalimumab by Countries
      • 10.1.1 Middle East and Africa LATAM Adalimumab Sales by Countries
      • 10.1.2 Middle East and Africa LATAM Adalimumab Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa LATAM Adalimumab by Product
    • 10.3 Middle East and Africa LATAM Adalimumab by End User

    11 Company Profiles

    • 11.1 AbbVie, Inc.
      • 11.1.1 AbbVie, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AbbVie, Inc. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AbbVie, Inc. LATAM Adalimumab Products Offered
      • 11.1.5 AbbVie, Inc. Recent Development
    • 11.2 Amgen, Inc.
      • 11.2.1 Amgen, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Amgen, Inc. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Amgen, Inc. LATAM Adalimumab Products Offered
      • 11.2.5 Amgen, Inc. Recent Development
    • 11.3 Boehringer Ingelheim GmbH
      • 11.3.1 Boehringer Ingelheim GmbH Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Boehringer Ingelheim GmbH LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Boehringer Ingelheim GmbH LATAM Adalimumab Products Offered
      • 11.3.5 Boehringer Ingelheim GmbH Recent Development
    • 11.4 Eisai Co., Ltd.
      • 11.4.1 Eisai Co., Ltd. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Eisai Co., Ltd. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Eisai Co., Ltd. LATAM Adalimumab Products Offered
      • 11.4.5 Eisai Co., Ltd. Recent Development
    • 11.5 Mylan N.V.
      • 11.5.1 Mylan N.V. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Mylan N.V. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Mylan N.V. LATAM Adalimumab Products Offered
      • 11.5.5 Mylan N.V. Recent Development
    • 11.6 Novartis AG
      • 11.6.1 Novartis AG Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Novartis AG LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Novartis AG LATAM Adalimumab Products Offered
      • 11.6.5 Novartis AG Recent Development
    • 11.7 Pfizer, Inc.
      • 11.7.1 Pfizer, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Pfizer, Inc. LATAM Adalimumab Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Pfizer, Inc. LATAM Adalimumab Products Offered
      • 11.7.5 Pfizer, Inc. Recent Development

    12 Future Forecast

    • 12.1 LATAM Adalimumab Market Forecast by Regions
      • 12.1.1 Global LATAM Adalimumab Sales Forecast by Regions 2019-2025
      • 12.1.2 Global LATAM Adalimumab Revenue Forecast by Regions 2019-2025
    • 12.2 LATAM Adalimumab Market Forecast by Product
      • 12.2.1 Global LATAM Adalimumab Sales Forecast by Product 2019-2025
      • 12.2.2 Global LATAM Adalimumab Revenue Forecast by Product 2019-2025
    • 12.3 LATAM Adalimumab Market Forecast by End User
    • 12.4 North America LATAM Adalimumab Forecast
    • 12.5 Europe LATAM Adalimumab Forecast
    • 12.6 Asia Pacific LATAM Adalimumab Forecast
    • 12.7 Central & South America LATAM Adalimumab Forecast
    • 12.8 Middle East and Africa LATAM Adalimumab Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 LATAM Adalimumab Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.
      Consistent technological sophistications in development of biosimilar followed by increasing incidence and prevalence of various medical conditions have rendered encouraging growth opportunities for various biological drugs and other innovative biopharmaceuticals. The LATAM adalimumab market by application has been categorized on the basis of the usage of adalimumab for treatment of various medical conditions.
      The global LATAM Adalimumab market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the LATAM Adalimumab market based on company, product type, end user and key regions.

      This report studies the global market size of LATAM Adalimumab in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of LATAM Adalimumab in these regions.
      This research report categorizes the global LATAM Adalimumab market by top players/brands, region, type and end user. This report also studies the global LATAM Adalimumab market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AbbVie, Inc.
      Amgen, Inc.
      Boehringer Ingelheim GmbH
      Eisai Co., Ltd.
      Mylan N.V.
      Novartis AG
      Pfizer, Inc.

      Market size by Product
      Oral Type
      Injection Type
      Market size by End User
      Rheumatoid Arthritis
      Psoriasis
      Crohn’s Disease
      Ulcerative Colitis
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global LATAM Adalimumab market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of LATAM Adalimumab market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global LATAM Adalimumab companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of LATAM Adalimumab submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of LATAM Adalimumab are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of LATAM Adalimumab market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now